Open AccessThe First Experience of Effective 3rd Line Antiretroviral Therapy – A Case of 40-Year-Old Female Retroviral-Infected Patient at Hawassa University Comprehensive Specialized Hospital, Hawassa, Sidama, Ethiopia
Author(s) -
Worku Ketema,
Kefyalew Taye,
Mulugeta Sitot Shibeshi,
Negash Tagesse,
Agete Tadewos Hirigo,
Kindie Woubishet,
Selamawit Gutema,
Aberash Eifa,
Alemayehu Toma
Publication year - 2021
Publication title -
research and reports in tropical medicine
Language(s) - English
Resource type - Journals
ISSN - 1179-7282
DOI - 10.2147/rrtm.s341711
Subject(s) - darunavir , ritonavir , dolutegravir , medicine , viral load , antiretroviral therapy , lamivudine , salvage therapy , virology , oncology , human immunodeficiency virus (hiv) , virus , chemotherapy , hepatitis b virus
Treatment failure continues to be an impediment to the efficacy of highly active antiretroviral therapy (HART) in the treatment of human immunodeficiency virus type 1 infection (HIV-1). The World Health Organization (WHO) recommends third-line antiretroviral therapy (ART) for patients who have failed second-line ART. Darunavir (DRV) boosted with ritonavir (DRV/r) has a higher genetic barrier to resistance, is active against multidrug-resistant HIV isolates, retaining virological activity even when multiple protease mutations are present, and has been shown to be cost-effective when compared to other boosted protease inhibitors (PIs).